BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

744 related articles for article (PubMed ID: 23455548)

  • 1. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin.
    Wang Y; Zheng D; Wei M; Ma J; Yu Y; Chen R; Lacefield JC; Xu H; Peng T
    Cardiovasc Res; 2013 Jun; 98(3):381-90. PubMed ID: 23455548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
    Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
    Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
    Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
    Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia.
    Li X; Li Y; Shan L; Shen E; Chen R; Peng T
    Cardiovasc Res; 2009 Jul; 83(1):72-9. PubMed ID: 19318376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain-2 promotes MKP-1 expression protecting cardiomyocytes in both in vitro and in vivo mouse models of doxorubicin-induced cardiotoxicity.
    Zheng D; Su Z; Zhang Y; Ni R; Fan GC; Robbins J; Song LS; Li J; Peng T
    Arch Toxicol; 2019 Apr; 93(4):1051-1065. PubMed ID: 30810770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway.
    Kim KH; Oudit GY; Backx PH
    J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.
    Gratia S; Kay L; Potenza L; Seffouh A; Novel-Chaté V; Schnebelen C; Sestili P; Schlattner U; Tokarska-Schlattner M
    Cardiovasc Res; 2012 Aug; 95(3):290-9. PubMed ID: 22461523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts.
    Zhang W; St Clair D; Butterfield A; Vore M
    Toxicol Sci; 2016 May; 151(1):44-56. PubMed ID: 26822305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of HMGB1 in doxorubicin-induced myocardial apoptosis and its regulation pathway.
    Yao Y; Xu X; Zhang G; Zhang Y; Qian W; Rui T
    Basic Res Cardiol; 2012 May; 107(3):267. PubMed ID: 22527657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone Antagonizes Doxorubicin-Induced Senescence of Cardiomyocytes.
    Altieri P; Barisione C; Lazzarini E; Garuti A; Bezante GP; Canepa M; Spallarossa P; Tocchetti CG; Bollini S; Brunelli C; Ameri P
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26746999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant low-dose doxorubicin treatment and exercise.
    Sturgeon K; Schadler K; Muthukumaran G; Ding D; Bajulaiye A; Thomas NJ; Ferrari V; Ryeom S; Libonati JR
    Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R685-92. PubMed ID: 25009215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.
    Mukhopadhyay P; Rajesh M; Bátkai S; Kashiwaya Y; Haskó G; Liaudet L; Szabó C; Pacher P
    Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1466-83. PubMed ID: 19286953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth.
    Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A
    Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calpain-1 induces endoplasmic reticulum stress in promoting cardiomyocyte apoptosis following hypoxia/reoxygenation.
    Zheng D; Wang G; Li S; Fan GC; Peng T
    Biochim Biophys Acta; 2015 May; 1852(5):882-92. PubMed ID: 25660447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein 20 interacting with phosphorylated Akt reduces doxorubicin-triggered oxidative stress and cardiotoxicity.
    Fan GC; Zhou X; Wang X; Song G; Qian J; Nicolaou P; Chen G; Ren X; Kranias EG
    Circ Res; 2008 Nov; 103(11):1270-9. PubMed ID: 18948619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL protects against doxorubicin-induced cardiotoxicity in a scavenger receptor class B type 1-, PI3K-, and Akt-dependent manner.
    Durham KK; Chathely KM; Mak KC; Momen A; Thomas CT; Zhao YY; MacDonald ME; Curtis JM; Husain M; Trigatti BL
    Am J Physiol Heart Circ Physiol; 2018 Jan; 314(1):H31-H44. PubMed ID: 28986362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion.
    Abdillahi M; Ananthakrishnan R; Vedantham S; Shang L; Zhu Z; Rosario R; Zirpoli H; Bohren KM; Gabbay KH; Ramasamy R
    Am J Physiol Heart Circ Physiol; 2012 Aug; 303(3):H297-308. PubMed ID: 22661511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
    Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
    Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.